M. Combettes-souverain and T. Issad, Molecular basis of insulin action, Diabetes Metab, vol.24, pp.477-489, 1998.

N. Chalhoub and S. Baker, PTEN and the PI3-Kinase Pathway in Cancer, Annual Review of Pathology: Mechanisms of Disease, vol.4, issue.1, pp.127-150, 2009.
DOI : 10.1146/annurev.pathol.4.110807.092311

C. Carpenter, K. Auger, M. Chanudhuri, M. Yoakim, and B. Schaffhausen, Phosphoinositide 3-kinase is activated by phosphopeptides that bind to the SH2 domains of the 85-kDa subunit, J Biol Chem, vol.268, pp.9478-9483, 1993.

N. Leslie and C. Downes, PTEN: The down side of PI 3-kinase signalling, Cellular Signalling, vol.14, issue.4, pp.285-295, 2002.
DOI : 10.1016/S0898-6568(01)00234-0

J. Engelman, Targeting PI3K signalling in cancer: opportunities, challenges and limitations, Nature Reviews Cancer, vol.16, issue.8, pp.550-562, 2009.
DOI : 10.1038/nrc2664

K. Mahajan, D. Coppola, S. Challa, B. Fang, and Y. Chen, Ack1 Mediated AKT/PKB Tyrosine 176 Phosphorylation Regulates Its Activation, PLoS ONE, vol.5, issue.3, p.9646, 2010.
DOI : 10.1371/journal.pone.0009646.s010

S. Fabre, V. Lang, J. Harriague, A. Jobart, and T. Unterman, Stable Activation of Phosphatidylinositol 3-Kinase in the T Cell Immunological Synapse Stimulates Akt Signaling to FoxO1 Nuclear Exclusion and Cell Growth Control, The Journal of Immunology, vol.174, issue.7, 2005.
DOI : 10.4049/jimmunol.174.7.4161

J. Harriague and G. Bismuth, Imaging antigen-induced PI3K activation in T cells, Nature Immunology, vol.3, issue.11, pp.1090-1096, 2002.
DOI : 10.1038/ni847

C. Pierre-eugene, P. Pagesy, T. Nguyen, M. Neuillé, and G. Tschank, Effect of Insulin Analogues on Insulin/IGF1 Hybrid Receptors: Increased Activation by Glargine but Not by Its Metabolites M1 and M2, PLoS ONE, vol.49, issue.Pt 3, p.41992, 2012.
DOI : 10.1371/journal.pone.0041992.s002

S. Kanwal, Y. Fardini, P. Pagesy, N. Tumba-byn, T. Pierre-eugène et al., O-GlcNAcylation-Inducing Treatments Inhibit Estrogen Receptor ?? Expression and Confer Resistance to 4-OH-Tamoxifen in Human Breast Cancer-Derived MCF-7 Cells, PLoS ONE, vol.29, issue.7, pp.69150-9539, 2013.
DOI : 10.1371/journal.pone.0069150.s004
URL : https://hal.archives-ouvertes.fr/hal-00866032

C. Blanquart, J. Achi, and T. Issad, Characterization of IRA/IRB hybrid insulin receptors using bioluminescence resonance energy transfer, Biochemical Pharmacology, vol.76, issue.7, pp.873-883, 2008.
DOI : 10.1016/j.bcp.2008.07.027

C. Blanquart, S. Karouri, and T. Issad, Implication of protein tyrosine phosphatase 1B in MCF-7 cell proliferation and resistance to 4-OH tamoxifen, Biochemical and Biophysical Research Communications, vol.387, issue.4, pp.748-753, 2009.
DOI : 10.1016/j.bbrc.2009.07.105

J. Liu, T. Issad, E. Chevet, D. Ledoux, and J. Courty, Priority paper Fibroblast growth factor-2 has opposite effects on human breast cancer MCF-7 cell growth depending on the activation level of the mitogen-activated protein kinase pathway, European Journal of Biochemistry, vol.258, issue.1, pp.271-276, 1998.
DOI : 10.1046/j.1432-1327.1998.2580271.x

T. Issad, M. Combettes, and P. Ferre, Isoproterenol Inhibits Insulin-Stimulated Tyrosine Phosphorylation of the Insulin Receptor Without Increasing its Serine/Threonine Phosphorylation, European Journal of Biochemistry, vol.4, issue.1, pp.108-115, 1995.
DOI : 10.1210/jc.77.1.73

N. Boute, K. Pernet, and T. Issad, Monitoring the activation state of the insulin receptor using bioluminescence resonance energy transfer, Mol Pharmacol, vol.60, pp.640-645, 2001.

D. Lacasa, N. Boute, and T. Issad, Interaction of the Insulin Receptor with the Receptor-Like Protein Tyrosine Phosphatases PTP?? and PTP?? in Living Cells, Molecular Pharmacology, vol.67, issue.4, pp.1206-1213, 2005.
DOI : 10.1124/mol.104.009514

S. Nouaille, C. Blanquart, V. Zilberfarb, N. Boute, and D. Perdereau, Interaction with Grb14 results in site-specific regulation of tyrosine phosphorylation of the insulin receptor, EMBO reports, vol.13, pp.512-518, 2006.
DOI : 10.1074/jbc.M208518200

M. Sommerfeld, G. Muller, G. Tschank, G. Seipke, and P. Habermann, In Vitro Metabolic and Mitogenic Signaling of Insulin Glargine and Its Metabolites, PLoS ONE, vol.5, issue.3, p.9540, 2010.
DOI : 10.1371/journal.pone.0009540.t001

N. Patil, M. Abba, and H. Allgayer, Cetuximab and biomarkers in non-smallcell lung carcinoma, Biologics, vol.6, pp.221-231, 2012.

T. Junttila, R. Akita, K. Parsons, C. Fields, L. Phillips et al., Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941, Cancer Cell, vol.15, issue.5, pp.429-440, 2009.
DOI : 10.1016/j.ccr.2009.03.020

J. Merlin, M. Barberi-heyob, and N. Bachmann, In vitro comparative evaluation of trastuzumab (Herceptin(R)) combined with paclitaxel (Taxol(R)) or docetaxel (Taxotere(R)) in HER2-expressing human breast cancer cell lines, Annals of Oncology, vol.13, issue.11, pp.1743-1748, 2002.
DOI : 10.1093/annonc/mdf263

C. Blanquart, N. Boute, D. Lacasa, and T. Issad, Monitoring the activation state of the insulin-like growth factor-1 receptor and its interaction with protein tyrosine phosphatase 1B using bioluminescence resonance energy transfer, Mol Pharmacol, vol.68, pp.885-894, 2005.

S. Boubekeur, N. Boute, P. Pagesy, V. Zilberfarb, and N. Christeff, A New Highly Efficient Substrate-trapping Mutant of Protein Tyrosine Phosphatase 1B (PTP1B) Reveals Full Autoactivation of the Insulin Receptor Precursor, Journal of Biological Chemistry, vol.286, issue.22, pp.19373-19380, 2011.
DOI : 10.1074/jbc.M111.222984

C. Vlahos, W. Matter, K. Hui, and R. Brown, A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4- one (LY294002), J Biol Chem, vol.269, pp.5241-5248, 1994.

B. Miao, I. Skidan, J. Yang, A. Lugovskoy, and M. Reibarkh, Small molecule inhibition of phosphatidylinositol-3,4,5-triphosphate (PIP3) binding to pleckstrin homology domains, Proceedings of the National Academy of Sciences, vol.107, issue.46, pp.20126-20131, 2010.
DOI : 10.1073/pnas.1004522107

M. Pollak, Endocrine effects of IGF-I on normal and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention, Breast Cancer Research and Treatment, vol.29, issue.3, pp.209-217, 1998.
DOI : 10.1023/A:1005950916707

Y. Fardini, E. Masson, O. Boudah, B. Jouira, R. Cosson et al., O-GlcNAcylation of FoxO1 in pancreatic ?? cells promotes Akt inhibition through an IGFBP1-mediated autocrine mechanism, The FASEB Journal, vol.28, issue.2, pp.1010-1021, 2014.
DOI : 10.1096/fj.13-238378
URL : https://hal.archives-ouvertes.fr/hal-01123110

Y. Zhang and R. Akhtar, Effect of Epidermal Growth Factor on Phosphatidylinositol 3-kinase Activity in Rabbit Corneal Epithelial Cells, Experimental Eye Research, vol.63, issue.3, pp.265-275, 1996.
DOI : 10.1006/exer.1996.0115

H. Jo, P. Lo, Y. Li, F. Loison, and S. Green, Deactivation of Akt by a small molecule inhibitor targeting pleckstrin homology domain and facilitating Akt ubiquitination, Proceedings of the National Academy of Sciences, vol.108, issue.16, pp.6486-6491, 2011.
DOI : 10.1073/pnas.1019062108

R. Stephen, L. Shaw, C. Larsen, D. Corcoran, and P. Darbre, Insulin-like Growth Factor Receptor Levels Are Regulated by Cell Density and by Long Term Estrogen Deprivation in MCF7 Human Breast Cancer Cells, Journal of Biological Chemistry, vol.276, issue.43, pp.40080-40086, 2001.
DOI : 10.1074/jbc.M105892200

A. De-cupis, D. Noonan, P. Pirani, A. Ferrera, and L. Clerico, Comparison between novel steroid-like and conventional nonsteroidal antioestrogens in inhibiting oestradiol- and IGF-I-induced proliferation of human breast cancer-derived cells, British Journal of Pharmacology, vol.3, issue.10, pp.2391-2400, 1995.
DOI : 10.1111/j.1476-5381.1995.tb15085.x

W. Roos, D. Fabbro, W. Kung, S. Costa, and U. Eppenberger, Correlation between hormone dependency and the regulation of epidermal growth factor receptor by tumor promoters in human mammary carcinoma cells., Proceedings of the National Academy of Sciences, vol.83, issue.4, pp.991-995, 1986.
DOI : 10.1073/pnas.83.4.991

Y. Imai, C. Leung, H. Friesen, and R. Shiu, Epidermal growth factor receptors and effect of epidermal growth factor on growth of human breast cancer cells in long-term tissue culture, Cancer Res, vol.42, pp.4394-4398, 1982.

C. Arteaga, S. Hurd, T. Dugger, A. Winnier, and J. Robertson, Epidermal growth factor receptors in human breast carcinoma cells: a potential selective target for transforming growth factor alpha-Pseudomonas exotoxin 40 fusion protein, Cancer Res, vol.54, pp.4703-4709, 1994.

G. Milazzo, F. Giorgino, G. Damante, C. Sung, and M. Stampfer, Insulin receptor expression and function in human breast cancer cell lines, Cancer Res, vol.52, pp.3924-3930, 1992.

G. Pandini, R. Vigneri, A. Costantino, F. Frasca, and A. Ippolito, Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling, Clin Cancer Res, vol.5, pp.1935-1944, 1999.

M. Soos, C. Field, and K. Siddle, Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity, Biochemical Journal, vol.290, issue.2, pp.419-426, 1993.
DOI : 10.1042/bj2900419

C. Blanquart, C. Gonzalez-yanes, and T. Issad, Monitoring the Activation State of Insulin/Insulin-Like Growth Factor-1 Hybrid Receptors Using Bioluminescence Resonance Energy Transfer, Molecular Pharmacology, vol.70, issue.5, pp.1802-1811, 2006.
DOI : 10.1124/mol.106.026989

R. Slaaby, L. Schaffer, I. Lautrup-larsen, A. Andersen, and A. Shaw, Hybrid Receptors Formed by Insulin Receptor (IR) and Insulin-like Growth Factor I Receptor (IGF-IR) Have Low Insulin and High IGF-1 Affinity Irrespective of the IR Splice Variant, Journal of Biological Chemistry, vol.281, issue.36, pp.25869-25874, 2006.
DOI : 10.1074/jbc.M605189200

K. Karey and D. Sirbasku, Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17 beta-estradiol, Cancer Res, vol.48, pp.4083-4092, 1988.

R. Pinkas-kramarski, L. Soussan, H. Waterman, G. Levkowitz, and I. Alroy, Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions, Embo J, vol.15, pp.2452-2467, 1996.

B. Kholodenko, O. Demin, G. Moehren, and J. Hoek, Quantification of Short Term Signaling by the Epidermal Growth Factor Receptor, Journal of Biological Chemistry, vol.274, issue.42, pp.30169-30181, 1999.
DOI : 10.1074/jbc.274.42.30169

A. Kiyatkin, E. Aksamitiene, N. Markevich, N. Borisov, and J. Hoek, Scaffolding protein Grb2-associated binder 1 sustains epidermal growth factorinduced mitogenic and survival signaling by multiple positive feedback loops, 2006.

Y. Toyoshima, H. Kakuda, K. Fujita, S. Uda, and S. Kuroda, Sensitivity control through attenuation of signal transfer efficiency by negative regulation of cellular signalling, Nature Communications, vol.22, p.743, 2011.
DOI : 10.1038/ncomms1745

N. Tebbutt, M. Pedersen, and T. Johns, Targeting the ERBB family in cancer: couples therapy, Nature Reviews Cancer, vol.5, issue.9, pp.663-673, 2013.
DOI : 10.1038/nrc3559

M. Martini, E. Ciraolo, F. Gulluni, and E. Hirsch, Targeting PI3K in Cancer: Any Good News?, Frontiers in Oncology, vol.3, p.108, 2013.
DOI : 10.3389/fonc.2013.00108

S. Moses, M. Ali, S. Zuohe, L. Du-cuny, and L. Zhou, In vitro and In vivo Activity of Novel Small-Molecule Inhibitors Targeting the Pleckstrin Homology Domain of Protein Kinase B/AKT, Cancer Research, vol.69, issue.12, pp.5073-5081, 2009.
DOI : 10.1158/0008-5472.CAN-08-3839

N. Berndt, H. Yang, B. Trinczek, S. Betzi, and Z. Zhang, The Akt activation inhibitor TCN-P inhibits Akt phosphorylation by binding to the PH domain of Akt and blocking its recruitment to the plasma membrane, Cell Death and Differentiation, vol.8, issue.11, pp.1795-1804, 2010.
DOI : 10.1083/jcb.200212113

N. Fortunati, M. Catalano, G. Boccuzzi, and R. Frairia, Sex Hormone-Binding Globulin (SHBG), estradiol and breast cancer, Molecular and Cellular Endocrinology, vol.316, issue.1, pp.86-92, 2010.
DOI : 10.1016/j.mce.2009.09.012
URL : https://hal.archives-ouvertes.fr/hal-00550178

M. Pollak, Insulin and insulin-like growth factor signalling in neoplasia, Nature Reviews Cancer, vol.5, issue.12, pp.915-928, 2008.
DOI : 10.2174/156800907781386623

G. Yang, H. Ge, A. Boucher, X. Yu, and C. Li, Modulation of Direct Leptin Signaling by Soluble Leptin Receptor, Molecular Endocrinology, vol.18, issue.6, pp.1354-1362, 2004.
DOI : 10.1210/me.2004-0027

N. Lahlou, T. Issad, Y. Lebouc, J. Carel, and L. Camoin, Mutations in the Human Leptin and Leptin Receptor Genes as Models of Serum Leptin Receptor Regulation, Diabetes, vol.51, issue.6, pp.1980-1985, 2002.
DOI : 10.2337/diabetes.51.6.1980

J. Symons, J. Eastgate, and G. Duff, Purification and characterization of a novel soluble receptor for interleukin 1, Journal of Experimental Medicine, vol.174, issue.5, pp.1251-1254, 1991.
DOI : 10.1084/jem.174.5.1251

S. Firth and R. Baxter, Cellular Actions of the Insulin-Like Growth Factor Binding Proteins, Endocrine Reviews, vol.23, issue.6, pp.824-854, 2002.
DOI : 10.1210/er.2001-0033

K. Kelley, Y. Oh, S. Gargosky, Z. Gucev, and T. Matsumoto, Insulinlike growth factor-binding proteins (IGFBPs) and their regulatory dynamics, 1996.

V. Frost, S. Helle, P. Lonning, J. Van-der-stappen, and J. Holly, Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulinlike growth factor (IGF) I and II, IGF-binding proteins (IGFBPs, p.3, 1996.

V. Panasiti, A. Naspi, V. Devirgiliis, M. Curzio, and V. Roberti, Correlation between insulin-like growth factor binding protein-3 serum level and melanoma progression, Journal of the American Academy of Dermatology, vol.64, issue.5, pp.865-872, 2011.
DOI : 10.1016/j.jaad.2010.03.035

G. Kuerzel, U. Shukla, H. Scholtz, S. Pretorius, and D. Wessels, Biotransformation of insulin glargine after subcutaneous injection in healthy subjects, Current Medical Research and Opinion, vol.19, issue.1, pp.34-40, 2003.
DOI : 10.1185/030079902125001416

A. Agin, N. Jeandidier, F. Gasser, D. Grucker, and R. Sapin, Glargine blood biotransformation: in??vitro appraisal with human insulin immunoassay, Diabetes & Metabolism, vol.33, issue.3, pp.205-212, 2007.
DOI : 10.1016/j.diabet.2006.12.002

G. Bolli, A. Hahn, R. Schmidt, T. Eisenblaetter, and R. Dahmen, Plasma Exposure to Insulin Glargine and Its Metabolites M1 and M2 After Subcutaneous Injection of Therapeutic and Supratherapeutic Doses of Glargine in Subjects With Type 1 Diabetes, Diabetes Care, vol.35, issue.12, pp.2626-2630, 2012.
DOI : 10.2337/dc12-0270

D. Mayer and E. Chantelau, ) increases the proliferative potency of the serum of patients with type-1 diabetes: a pilot study on MCF-7 breast cancer cells, Archives of Physiology and Biochemistry, vol.67, issue.2, pp.73-78, 2010.
DOI : 10.1002/dmrr.912